Brain cancer clinical trial gives hope to patients

Published:

Queensland researchers have found that patients who received a cellular immunotherapy for the deadly brain cancer glioblastoma multiforme (GBM) in a clinical trial on average survived longer than would have been expected without the treatment.

The team also found the treatment was safe and identified clues that will help them improve it in future.

The results of the phase I clinical trial have been published in the Journal of Clinical Investigation.

GBM is the most common malignant brain tumour in adults. It is a particularly aggressive cancer that usually recurs quickly after treatment. Patients survive an average of 14-17 months after diagnosis.

The cellular immunotherapy was developed by the head of QIMR Berghofer’s Centre for Immunotherapy and Vaccine Development, Professor Rajiv Khanna AO, and his team.

It was tested in a phase I (safety) clinical trial of 25 patients at Briz Brain and Spine in collaboration with neurosurgeon Professor David Walker.

Professor Khanna said the patients were given the immunotherapy as a supplementary treatment after receiving surgery, chemotherapy and/or radiation.

“At the end of this clinical trial, 10 patients were still alive and five of those still had no signs of their cancer recurring,” Professor Khanna said.

“The 25 patients who received the treatment survived for an average of 21 months. This is an improvement on the current survival rates.

“The results were even better in the 20 patients who received the immunotherapy before their tumours had recurred. Those patients survived for an average of 23 months, which is six to nine months better than we would have expected without this treatment.

“Considering GBM is a highly deadly cancer, these are very promising results.”

Neurosurgeon Professor David Walker said the trial had confirmed the treatment was safe for use in GBM patients.

“None of the patients experienced any adverse effects from the immunotherapy, which gives us confidence in progressing further clinical trials,” Professor Walker said.

“We have previously conducted another clinical trial where we gave this treatment to patients after their GBM had already recurred following initial treatment.

“While that earlier trial prolonged survival, in this trial, we were excited to see that some patients who received the immunotherapy earlier, before recurrence, had further improvements in survival.

“Brain cancer survival rates have hardly changed in decades. This trial gives us hope that we might be on the cusp of changing that.”

The cellular immunotherapies are produced by taking blood samples from patients and ‘turbo-charging’ their immune cells, known as T cells, in the laboratory to recognise and destroy the cytomegalovirus (CMV), which is present in the tumour cells.

Professor Khanna said they found the patients who survived had better T cell immunity to the cytomegalovirus.

“The treatment each patient received was produced with their own immune cells.

“We did a genomic analysis of each patient’s immunotherapy and found that patients with certain gene signatures inside their immune cells had better results.

“This is important because it tells us what improves the quality of these cellular immunotherapies and lets us know what markers we should be looking for in patients’ cells.

“It also opens the door to producing cellular immunotherapies using healthy donor immune cells that contain those gene signatures.”

Queensland’s Deputy Premier and Minister for Health, Steven Miles, has welcomed the promising results.

“Brain cancers are usually aggressive and have poor survival outcomes, so any new treatment that prolongs patients’ lives is very welcome,” Mr Miles said.

“It is great to see Queensland’s medical research institute working at the global forefront of research into immunotherapy.”

As a next step, the team hopes to conduct another clinical trial combining the cellular immunotherapies with other forms of immunotherapy.

The cellular immunotherapies were produced at QIMR Berghofer’s specialist cell manufacturing facility, Q-Gen Cell Therapeutics.

The trial was funded by the National Health and Medical Research Council (NHMRC) and philanthropic donors.

The results can be viewed on the Journal of Clinical Investigation website.

 
Community Health & Wellness Science & Research
Social:   

QIMR Berghofer Medical Research Institute :
PO Royal Brisbane Hospital, Brisbane, QLD, 4029, Brisbane
07 3845 3752
QIMR Berghofer Medical Research Institute
Showing 10+ recent articles for this business
No genetic signs that hearing loss causes Alzheimer’s disease 14 October 2020 | New QIMR Berghofer and QUT research has found there is no strong genetic evidence that hearing loss causes Alzheimer’s disease, despite both conditions sharing a significant number of genetic variants. More information...
Some school anti-bullying programs may do more harm than good 23 October 2020 | New QIMR Berghofer analysis of research on school anti-bullying programs has concluded that programs that encourage bystanders to intervene may inadvertently harm the children they are aimed at protecting. More information...
Melanoma risk not as obvious as some think 20 October 2020 | New QIMR Berghofer research has found almost a quarter of the Queensland population underestimates their risk of developing potentially deadly melanomas – with those at highest risk also the worst at predicting... More information...
Study finds ways to reduce the risk of common Queensland skin tumour 08 October 2020 | New QIMR Berghofer research has found limiting sun exposure, quitting smoking and cutting down on alcohol could help Queenslanders avoid developing the common skin tumour keratoacanthoma (KA). More information...
Researchers get a better grip on left and right handedness 29 September 2020 | In the largest study of its kind to date, researchers have identified 48 genetic variants that influence if a person is left-handed, right-handed or ambidextrous. More information...
New potential weapon found in battle against cancer and inflammatory diseases 24 August 2020 | QIMR Berghofer-led research has discovered the pivotal role played by an important immune system protein that, if harnessed through immunotherapy, has the potential to treat a wide range of cancers and inflamma... More information...
Brain cancer clinical trial gives hope to patients 13 August 2020 | Queensland researchers have found that patients who received a cellular immunotherapy for the deadly brain cancer glioblastoma multiforme (GBM) in a clinical trial on average survived longer than would have been... More information...
Pessimistic outlook on life linked to life expectancy 29 July 2020 | A new QIMR Berghofer Medical Research Institute study has found people who are strongly pessimistic about the future are at greater risk of dying earlier than those who are not pessimists. More information...
New keys found for unlocking head and neck cancer treatment 28 July 2020 | QIMR Berghofer scientists say the discovery of new cellular immunotherapy targets for a deadly type of head and neck cancer, caused by human papillomavirus (HPV), could lead to better survival rates. More information...
Scientists identify new target for melanoma immunotherapy 30 June 2020 | QIMR Berghofer research has found a new reason why some melanoma patients do not respond well to immunotherapy – a discovery that could lead to better-tailored treatments for the potentially deadly cancer. More information...


comments powered by Disqus

All articles submitted by third parties or written by My Sunshine Coast come under our Disclaimer / Terms of Service